Canntab Therapeutics Limited
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulation… Read more
Canntab Therapeutics Limited (CTABF) - Total Liabilities
Latest total liabilities as of February 2023: $3.11 Million USD
Based on the latest financial reports, Canntab Therapeutics Limited (CTABF) has total liabilities worth $3.11 Million USD as of February 2023.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Canntab Therapeutics Limited - Total Liabilities Trend (2011–2022)
This chart illustrates how Canntab Therapeutics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Canntab Therapeutics Limited Competitors by Total Liabilities
The table below lists competitors of Canntab Therapeutics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CAP LEASE AVIATION
LSE:CLA
|
UK | GBX2.71 Million |
Liability Composition Analysis (2011–2022)
This chart breaks down Canntab Therapeutics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Canntab Therapeutics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Canntab Therapeutics Limited (2011–2022)
The table below shows the annual total liabilities of Canntab Therapeutics Limited from 2011 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-05-31 | $3.16 Million | -22.70% |
| 2021-05-31 | $4.09 Million | +106.63% |
| 2020-05-31 | $1.98 Million | +508.17% |
| 2019-05-31 | $325.63K | -27.13% |
| 2018-05-31 | $446.89K | +183.43% |
| 2017-12-31 | $157.68K | +59.72% |
| 2017-05-31 | $98.72K | +20.07% |
| 2016-12-31 | $82.22K | -79.59% |
| 2016-05-31 | $402.83K | +65.80% |
| 2015-05-31 | $242.96K | +91.49% |
| 2014-05-31 | $126.88K | +59.04% |
| 2013-05-31 | $79.78K | -18.63% |
| 2012-05-31 | $98.04K | -18.90% |
| 2011-05-31 | $120.89K | -- |